Abstract 404P
Background
Cancers in AYA is being recognized as a disenfranchised niche field with its own unique epidemiology, cancer biology, risk factors, treatment implications & the massive socio-economic impact it bears on this most economically productive age-group. There is a paucity of well-collated published data from developing countries. Our study has tried to compile & analyze the pattern of AYA cancers from a large rural tertiary care teaching-hospital in South India & compare it to the published national data.
Methods
We compiled & analyzed the burden of AYA cancers in terms of demographic & site distribution, proportion, histopathologic diagnosis & other parameters over Jan.2019 to Dec.2022 from the medical records of large rural tertiary care teaching-hospital in South India. We compared our data on AYA cancers vis-à-vis the published national statistics.
Results
A total of 7973 patients were diagnosed with cancer between Jan.2019 to Dec.2022, 983(12.3%) occurred in AYA. 544(55.3%) were females. 104(10.6%), 126(12.9%), 153(15.5%), 226(23%) & 374(38.0%) occurred in the 15-19, 20-24, 25-29, 30-34 & 35-39 age groups respectively. The most common cancer overall was hematolymphoid malignancy(201, 20.4%), followed by thyroid(188, 19.12%). The most common hematolymphoid malignancy is acute leukaemia followed by non-Hodgkin lymphoma. The most common thyroid neoplasm was papillary thyroid carcinoma. Other common malignancies included Breast(113, 11.5%), Oral cavity(79, 8%), Central nervous system(65, 6.6%) & lower gastrointestinal tract(48, 4.9%).
Conclusions
AYA cancers deserve organizational support, multicenter collaboration, & resource-appropriate treatment adaptations with dedicated survivorship clinics. Mapping the epidemiology of AYA cancers will help improve surveillance, further focussed research & collaboration, guide resource allocation and national health policies, thus ultimately improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Vishwapriya Mahadev Godkhindi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06